Author:
Rush Everett,Ozmen Ozgur,Kim Minsu,Ortegon Erin Rush,Jones Makoto,Park Byung H.,Pizer Steven,Trafton Jodie,Brenner Lisa A.,Ward Merry,Nebeker Jonathan R.
Abstract
Abstract
Background
To discover pharmacotherapy prescription patterns and their statistical associations with outcomes through a clinical pathway inference framework applied to real-world data.
Methods
We apply machine learning steps in our framework using a 2006 to 2020 cohort of veterans with major depressive disorder (MDD). Outpatient antidepressant pharmacy fills, dispensed inpatient antidepressant medications, emergency department visits, self-harm, and all-cause mortality data were extracted from the Department of Veterans Affairs Corporate Data Warehouse.
Results
Our MDD cohort consisted of 252,179 individuals. During the study period there were 98,417 emergency department visits, 1,016 cases of self-harm, and 1,507 deaths from all causes. The top ten prescription patterns accounted for 69.3% of the data for individuals starting antidepressants at the fluoxetine equivalent of 20-39 mg. Additionally, we found associations between outcomes and dosage change.
Conclusions
For 252,179 Veterans who served in Iraq and Afghanistan with subsequent MDD noted in their electronic medical records, we documented and described the major pharmacotherapy prescription patterns implemented by Veterans Health Administration providers. Ten patterns accounted for almost 70% of the data. Associations between antidepressant usage and outcomes in observational data may be confounded. The low numbers of adverse events, especially those associated with all-cause mortality, make our calculations imprecise. Furthermore, our outcomes are also indications for both disease and treatment. Despite these limitations, we demonstrate the usefulness of our framework in providing operational insight into clinical practice, and our results underscore the need for increased monitoring during critical points of treatment.
Funder
U.S. Department of Veterans Affairs
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7.
2. McQuaid JR, Buelt A, Capaldi V, Fuller M, Issa F, Lang AE, et al. The management of major depressive disorder: synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2022;175(10):1440–51. https://doi.org/10.7326/M22-1603.
3. Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, et al. The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). PharmacoEconomics. 2021;39(6):653–65. https://doi.org/10.1007/s40273-021-01019-4.
4. NIMH. 2019 NSDUH Annual National Report | CBHSQ Data. National Institute of Mental Health; 2019.
5. National Academies of Sciences E, Division HaM, Services BoHC, Services CtEtDoVAMH. Clinical management of mental health conditions at the veterans health Adminstration. In: evaluation of the department of veterans affairs mental health services. National Academies Press (US); 2018. https://www.ncbi.nlm.nih.gov/books/NBK499504/. Accessed 9 Feb. 2022.